Canakinumab is a human monoclonal anti-IL-1β antibody, approved for use in cryopyrin-associated periodic syndromes (CAPS) (an IL-1β driven inflammatory disease) and under investigation for use in rheumatoid arthritis, systemic juvenile idiopathic arthritis and refractory gout. Here, IL1B is linked to cryopyrin-associated periodic syndrome.